Neurodegenerative disease models

Slides:



Advertisements
Similar presentations
Sporadic AD familial AD etiology environmental factors, genetic predisposition etiology oligomerization of A 42 and initial (diffuse) A 42 deposits subtle.
Advertisements

The Role of Calcium in Ischemic Brain Damage: By: Christian Stork.
ALZHEIMER’S DISEASE Erin Dancey. Overview Alzheimer’s is the most common cause of dementia in adult life and is associated with the selective damage of.
Apoptosis By Dr Abiodun Mark .A.
ALZHEIMER'S DISEASE (AD)
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Parkinson’s Disease Pathology 430/826 The Molecular Basis of Disease Neurological Genetics 9 th March 2015 Dr. John Rossiter
Alzheimer’s Disease Find group of ~4 students ~ 10 minutes Discuss the following personal family connection to AD (if willing only) observations/experiences.
Chapter 21. Molecular Mechanisms of Neurological Disease Copyright © 2014 Elsevier Inc. All rights reserved.
Diseases that Result from Abnormal Mitochondrial Function Lu Qiping April 15, 2011.
Mechanisms of Ischemic Brain Damage Jenn Mejilla.
Parkinson’s Disease superKAT :).
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
New Cellular Models for Drug Discovery in Alzheimer’s Disease Jordan L. Holtzman, M.D.,Ph.D. 1,2,3 (1) Division of Environmental Health Sciences (2) Departments.
Trafficking and processing of APP  -secretase. Intracellular trafficking of APP: relation to its physiological function?
Trafficking and processing of APP  and  -secretase.
Under the supervision of miklós jászberényi
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
By: London Seigle & Marlinda Reakes. Structure of Cytoskeleton  Long, twisted strands (criss-crossing)  A cellular, scaffolding structure  Found within.
Pathogenesis and pathology of parkinsonism
STEM CELL RESEARCH ON HUNTINGTON’S DISEASE Josh Merrifield, Michael Jennings, and Stephanie Antone.
Genetic aspects of Alzheimer disease Karolina Pesz, Błażej Misiak, Maria M. Sasiadek Department of Genetics Wroclaw Medical University, Poland.
Section 7.4 Effects of Aging. Introduction 1. The nervous system is formed during the first month of embryonic development 2. Any maternal infection can.
Parkinson’s Disease.
Preston Ge Institute for Cell Engineering
CLINICAL CORRELATIONS
Module 7.3 Movement Disorders
Protein conformational disorders
By the end of this section you will be able to …..
CLINICAL CORRELATIONS
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Alzheimer’s Disease CNS Block.
Tejaswini Katravulapalli BNFO 300
Alzheimer’s Disease.
Nitric Oxide (NO) and How it Regulates Motor Function
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
III. Parkinson Disease.
Alpha-synuclein in Parkinson's disease
Cell Communication.
Figure Adenylyl cyclase Phosphodiesterase Pyrophosphate AMP
Cell Communication.
Neurotransmitters (NT)
Parkinson’s Common neurodegenerative disorder ~10-20/1000
What does this protein make up or do?
Gene expression, LTP, ion channels, enzymes, cell death
Basal ganglia function
Cell Communication.
Acetylation Unleashes Protein Demons of Dementia
Cell Communication.
Mitochondria in Neuroplasticity and Neurological Disorders
ION CHANNELS AS DRUG TARGETS &
Cell Communication.
CLINICAL CORRELATIONS
Volume 72, Issue 1, Pages 9-21 (October 2011)
Figure 3 VEGF in neurodegenerative disease
Parkinson's Disease Neuron
Group 1 mGluR-Dependent Synaptic Long-Term Depression: Mechanisms and Implications for Circuitry and Disease  Christian Lüscher, Kimberly M. Huber  Neuron 
The Vacuolar H+-ATPase Mediates Intracellular Acidification Required for Neurodegeneration in C. elegans  Popi Syntichaki, Chrysanthi Samara, Nektarios.
Cell Communication.
Cell Communication.
Alzheimer's.
Neurodegenerative diseases
Mechanisms Underlying Inflammation in Neurodegeneration
Rab GTPases and Membrane Trafficking in Neurodegeneration
Alzheimer’s Disease Neurobiology
The Ubiquitin Proteasome System in Neurodegenerative Diseases
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
Linking Calcium to Aβ and Alzheimer's Disease
Presentation transcript:

Neurodegenerative disease models

Neurodegeneration models in C.elegans The development of transgenic models, has been intensively used for investigating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease and tauopathies. In some of these cases, the underlying genes do not have readily recognizable orthologues in C. elegans. Nevertheless, conserved responses or interactions can often be detected.

Neurodegeneration models in C.elegans Kaletta et al. Nature Reviews Drug Discovery advance online publication; published online 21 April 2006 | doi:10.1038/nrd2031

Alzheimer’s disease (AD) The g-secretase protein quartet, and its roles in brain development and Alzheimer's disease. Presenilin-1, nicastrin, APH-1 and PEN-2 form a functional g-secretase complex, located in the plasma membrane and endoplasmic reticulum (ER) of neurons. The complex cleaves Notch (left) to generate a fragment (NICD) that moves to the nucleus and regulates the expression of genes involved in brain development and adult neuronal plasticity. The complex also helps in generating the amyloid b-peptide (Ab; centre). This involves an initial cleavage of the amyloid precursor protein (APP) by an enzyme called BACE (or b-secretase). The g-secretase then liberates Ab, as well as an APP cytoplasmic fragment, which may move to the nucleus and regulate gene expression. Mutations in presenilin-1 that cause early-onset Alzheimer's disease enhance g-secretase activity and Ab production, and also perturb the ER calcium balance. Consequent neuronal degeneration may result from membrane-associated oxidative stress, induced by aggregating forms of Ab (which create Ab plaques), and by the perturbed calcium balance. Mattson, M. 2003 Nature

Alzheimer’s disease model The Aβ1-42 fragment is the main neurotoxic peptide generated from APP Invertebrate APP-like genes do not include the region encoding the neurotoxic Aβ1-42 fragment and, therefore, direct disease modelling based on endogenous APP cleavage is not possible. The most developed invertebrate model of Aβ1-42 toxicity involves intracellular expression of a human Aβ1-42 fragment in the C. elegans bodywall muscle, leading to adult-onset progressive paralysis and shortened lifespan In the nematode model, Aβ1-42 forms cytoplasmic β -amyloid with some properties similar to those found in diseased human brains

Model of age-related protection against proteotoxicity Cohen et al. 2006 DAF-2 represses two downstream pathways: transcription factor HSF-1 and transcription factor DAF-16. Both provide protection against proteotoxicity of the amyloid 42 peptide, an aggregation-prone peptide that can spontaneously form small toxic aggregates. The default pathway, regulated by HSF-1, identifies and breaks apart toxic aggregates. When the HSF-1 machinery is overloaded, however, a molecular apparatus regulated by DAF-16 leads to formation of less toxic high-molecular-weight aggregates.

Parkinson’s disease PD is the most common neurodegenerative movement disorder. Approximately 1% of the population older than 65 years suffers from this slowly progressive neurodegenerative disease; 95% of PD cases are sporadic. The symptoms of PD are caused by selective and progressive degeneration of pigmented dopaminergic (DA) neurons in the substantia nigra pars compacta. Current treatments, such as administration of L-DOPA to produce dopamine, are only symptomatic and do not stop or delay the progressive loss of neurons. In fact, some studies have suggested that oxidative injury via dopamine may lead to further neuronal damage. 7 known genetic loci. PARK1 is mutation in the gene for α-synuclein (synaptic vesicle fusion). PARK2 is mutation in parkin, the ubiquitin ligase for a-synuclein. The α-synuclein protein is also seen in Alzheimer’s plaques.

C. elegans Parkinson’s disease models C. elegans has 302 neurons of which 8 are dopaminergic Expression of a human gene encoding the PD-associated protein, alpha-synuclein, in C. elegans neurons results in dosage and age-dependent neurodegeneration -synuclein-induced dopaminergic neurodegeneration could be rescued in these animals by torsinA, a protein with molecular chaperone activity http://www.jove.com/index/details.stp?ID=835

Phenotypes in a worm model of human PD postural and movement deficits loss of neurons Lakso et al., 2003

up-regulated mitochondrial and proteasomal genes

C. elegans Parkinson’s disease models Impact of 6-hydroxydopamine (6-OHDA) on dopamine (DA) neurons in C. elegans intact green-fluorescing DA neurons in an untreated worm similar worm three days after exposure to 6-OHDA The partial loss of green fluorescence is indicative of progressive death of the dopamine neurons - due to destructive reactive oxygen species produced by 6-OHDA Nass et al., 2002 PNAS

6-OHDA has been found in brain and urine samples of PD patients DA transporter (DAT-1) in C. elegans is essentially the same, structurally and genetically, as the one found in mammals Blocking DAT-1 function through drugs or by genetic disruption eliminates 6-OHDA-sensitivity in the worms These results suggest that the toxic effect of 6-OHDA occurs after it enters the DA neuron. 6-hydroxydopamine

Huntington disease (HD) HD affects medium sized spiny neurons Uncontrollable growth of dendrites causes neurons to malfunction Parts of the brain affects include the cortex and basal ganglia, particular the caudate nucleus and the striatum Symptoms: Involuntary chorei-form (dance-like) movements, psychological change, dementia Treatment aimed at symptoms, drugs that are helpful at one stage may not work at another stage Death usually occurs 15 to 20 years after onset of symptoms People die of complications to HD not HD itself - choking, infections, heart failure, pneumonia

HD is a monogenic disease The disease is associated with increases in the length of a CAG triplet repeat present in a gene called 'huntingtin' (IT15) located on chromosome 4p16. Wild-type huntingtin has a role in membrane trafficking in the cytoplasm and is also involved in microtubule-based axonal transport. The range of CAG repeat numbers is 9 to 37 in normal individuals and 37 to 86 in HD patients. Huntingtin (Htt) domain model indicating the location of the polyQ repeat, proline-rich domain (PRD) and HEAT repeats. Selected interaction partners are listed for the polyQ and PRD region as well as the N-terminal region, including the first HEAT repeat section

Mutant huntingtin binds to synaptic vesicles with higher affinity than does wild-type huntingtin and inhibits the uptake of glutamate by synaptic vesicles, suggesting that it might be able to affect synaptic homeostasis directly. Aggregates containing mutant huntingtin are usually located in the nucleus and cytoplasm, but they can also appear in the axon and nerve terminals.

Immunoblot showing anti-GFP immunoreaction in C Immunoblot showing anti-GFP immunoreaction in C. elegans protein extracts using 3–4-day-old animals expressing different lengths of GFP–Htt–polyQ proteins GFP fluorescence micrographs of young adult (3–4 days old) C. elegans expressing different lengths of GFP–polyQ fusion proteins. Note that GFP fluorescence is mainly localized to the body wall muscle cells. Also, note that more compact foci form with increasing number of polyQ repeats expressed Wang, H. et al. 2006 Hum. Mol. Genet.

C) Higher magnification showing the body wall of young adult C C) Higher magnification showing the body wall of young adult C. elegans expressing different lengths of GFP–polyQ fusion proteins D) Motility assay measured as body bends per minute in wild-type and various transgenic lines of adult C. elegans. Note that the rate of movement decreases with increasing length of polyQ repeats.

Ion-channel-mediated neurotoxicity If neurons are deprived of oxygen and the ATP stores drop, excess excitatory neurotransmitter glutamate is released into the synapse. Glutamate transporters, which usually rapidly clear synaptic glutamate, also fail to function appropriately in these conditions, leading to hyperactivation of glutamate-gated ion channels, excess ion influx, neuronal swelling and death. In C. elegans, a mutant acetylcholine receptor Ca2+ channel DEG-3(d), and hyperactivated mutant variants of the degenerin Na+ channels cause neuronal swelling and death Transgenic expression of constitutively active GTPase-defective heterotrimeric G protein Gs can also induce necrotic-like neuronal death Because G proteins are known to influence ion-channel activity, Gs might induce neuronal degeneration by ion-channel hyperactivation

Hyperactivated ion channels, such as the MEC-4(d) Na+ channel, the DEG-3(d) Ca2+ channel and possibly other channels that are affected if Gs is constitutively activated, conduct excess ions into neurons. This might induce the secondary release of calcium through ryanodine receptor (UNC-68) or InsP3R receptor (ITR-1) from ER stores, where it is bound by the ER chaperone proteins calreticulin and calnexin If intracellular calcium levels rise, specific calpain and aspartyl proteases are activated and the cell ultimately undergoes a necrotic death. In mammalian models of ischaemia and excitotoxic cell death, as well as in human neurodegenerative disease, activation of Ca2+-activated calpain proteases is crucial for necrotic demise